Sen. Pat Toomey (R-Pa.), who was a key player in writing the financial portions of the CARES Act, applauded Mnuchin’s decision. “Congress’s intent was clear: these facilities were to be temporary, to provide liquidity, and to cease operations by the end of 2020. With liquidity restored, they should expire, as Congress intended and the law requires, by December 31, 2020,” he said.
The Best and Worst Places to Be in the Coronavirus Era By Rachel Chang, Jinshan Hong and Kevin Varley November 24, 2020 As Covid-19 has spread around the world, it’s challenged preconceptions about which places would best tackle the worst public health crisis in a generation. Advanced economies like the U.S. and U.K., ranked by various pre-2020 measures as being the most prepared for a pandemic, have been repeatedly overwhelmed by infections and face a return to costly lockdowns. Meanwhile, other countries—even developing nations—have defied expectations, some all but eliminating the pathogen within their borders. Bloomberg crunched the numbers to determine the best places to be in the coronavirus era: where has the virus been handled most effectively with the least amount of disruption to business and society? Covid-19 Resilience Ranking (Covid Status) Covid-19 Resilience Ranking (Quality of Life) https://www.bloomberg.com/graphics/covid-resilience-ranking/?utm_source=pocket-newtab wrbtrader
We were lectured 24/7 about the evils of gathering on Thanksgiving, super spreaders, killing grand-ma etc..... But not a word about shopping, Black Friday, stores full of people.......
https://www.washingtonexaminer.com/...ed-with-controversial-drug-hydroxychloroquine Study finds 84% fewer hospitalizations for patients treated with controversial drug hydroxychloroquine A peer-reviewed study measuring the effectiveness of a controversial drug cocktail that includes hydroxychloroquine concluded that the treatment lowered hospitalizations and mortality rates of coronavirus patients. The study, set to be published in the International Journal of Antimicrobial Agents in December, determined that “Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.”
As noted.... they cherry picked the group to obtain the results. "A total of 141 diagnosed COVID-19 patients were prescribed the triple treatment over a five-day period. They were compared with a control group of 377 confirmed COVID-19 patients who did not receive the treatment." Ignoring the tens of thousand of documented patients that provide the exact opposite results. Of course, the author, Dr. Vladimir Zelenko, has been pushing hydroxychloroquine and other debunked COVID nonsense. Dr. Vladimir Zelenko lost his practice in New York after falsely promoting HCQ. https://www.theblaze.com/news/peer-reviewed-hydroxychloroquine-study-hospitalizations ‘Miracle drug’ Dr. Vladimir Zelenko is tweeting pro-Trump conspiracy theories https://forward.com/fast-forward/451823/dr-vladimir-zelenko-hydroxychloroquine-surgery/ Why Dr. Vladimir Zelenko staked his reputation on hydroxychloroquine https://forward.com/news/national/447109/zelenko-hydroxychloroquine-trump/
Surprise! Now that Big Pharma has their vaccines ready to distribute and enough media narrative to push them at tax payer expense, all the beneficial treatments that would have slowed or downplayed the need for a lifesaving vaccine can now be allowed in the public domain.
Thank you WeToddDid2! I wondered about this for quite a while and its nice to see that it's being shown!---Ishmael.
Most of these "miracle drugs" don't pan out when fully tested on humans. Here is an example of one from Georgia State University showing some promise that is being developed with involvement from Ridgeback Biotherapeutics and Merck. GSU researchers say new drug completely suppresses COVID-19 transmission https://www.wsbtv.com/news/local/at...d-19-transmission/UASJIOG4SRB6TDAZM5DKVHHK2I/ Researchers at Georgia State University say they have discovered a new antiviral drug that completely suppresses transmission of COVID-19 within 24 hours. The drug, called Molnupiravir (MK-4482/EIDD-2801), is taken orally as a pill. Channel 2′s Tom Regan was at GSU, where he talked to Dr. Richard Plemper, the lead on the study. “This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” Plemper said. “MK-4482/EIDD-2801 could be game-changing.” Plemper said the drug rapidly shuts down the replication of the virus in the body, derailing it to the point that the person is no longer contagious and can’t spread to other people. Researchers said the drug can also inhibit COVID-19 patients from getting severely ill. “From our animal model data, the drug will reduce the likelihood that a patient progresses to severe disease from viral pneumonia to potentially lethal consequences of COVID-19, so that’s a direct benefit to the patient,” Plemper said. Plemper said that while the drug is no substitute for a vaccine, it could be very effective in slowing down the spread of the virus until a vaccine is widely distributed next year. Researchers tested the drugs on ferrets and it is now in human trials. Researchers said based on that study, COVID-19 patients treated with the drug could become noninfectious within 24 hours after the beginning of treatment. Molnupiravir is currently in advanced phase II/III clinical trails. Ridgeback Biotherapeutics has licensed the medicine and is developing it in collaboration with Merck. It’s unclear when the drug might be available to the public.
Yep. That drug comes with a bit of a convoluted history too, which is left out of that article. At least I think this is the same drug. https://bgr.com/2020/07/31/coronavirus-cure-merck-mk-4482-eidd-2801-rick-bright-controversy/